[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cervical-intraepithelial-neoplasia-cin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cervical-intraepithelial-neoplasia-cin":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,74,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100638783","testing-the-feasibility-of-different-hpv-screening-and-care-strategies-for-women-living-with-hiv-100638783",false,"NCT07576842","Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIV","CASCADE: A Feasibility Study of HPV Screening and Management Strategies Utilizing Extended Molecular HPV DNA Genotyping and HPV Viral Load in Women Living With HIV","Inclusion Criteria:\n\n* HIV-1 infection, as documented by:\n\n  1. any FDA-approved, licensed HIV rapid test performed in conjunction with screening (oral immunoblot, ELISA test kit, and confirmed by Western blot or other approved test), OR\n  2. a physician's written record that documents HIV infection with supporting information on the participant's relevant medical history and\u002For current management of HIV infection, OR\n  3. documentation of a prescription of an approved antiretroviral regimen by either possession of pill bottles or packages with prescriber's name or ARVs dispensed from an HIV clinical treatment program with participant identifiers affixed to the bottles or packages.\n* Aged 25 or older.\n* Ability to understand and the willingness to sign a written informed consent document by the participant or by the legal representative(s) of the participant.\n* Have an intact cervix.\n\nExclusion Criteria:\n\n* Current symptoms or concern for cervical cancer.\n* History of cervical, vulvar, vaginal, perianal, anal cancer or oral cancer or current symptoms of cervical, vulvar, vaginal, perianal, anal cancer or oral cancer.\n* Have undergone cervical hHSIL treatment in the past year.\n* Have a history of hysterectomy with removal of the cervix.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (including opportunistic infections of AIDS and\u002For genitourinary infections), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Any other medical condition or social situation that would put the participant, the study staff, or the study outcomes at risk, as determined by the site investigators.","FEMALE","25 Years",{"count":19,"type":20},750,"ESTIMATED","INTERVENTIONAL",[23],"NA","The overall goal of this study is to inform the design and establish feasibility for a future clinical trial to determine the optimal management of women living with HIV (WLWH) with high-risk human papillomavirus (hrHPV) detected on HPV-based cervical cancer screening. WLWH have a higher diversity of anogenital HPV types causing cervical high-grade squamous intraepithelial lesions (hHSIL) and invasive cancer compared to women without HIV. While there is consensus that women testing positive for HPV 16 and\u002For 18 should be immediately managed and treated, optimal management strategies for women with other hrHPV types (non-16\u002F18) are not well defined.\n\nThis prospective cohort study will enroll WLWH undergoing cervical cancer screening using primary HPV testing. Women will self-collect vaginal specimens for hrHPV testing using the Abbott Alinity m HPV assay, which provides extended HPV genotyping and a proxy for HPV viral load based on cycle threshold (CT) values. Women with hrHPV detected will return for further evaluation and treatment as indicated. A subset of women will return at Month 6 for repeat evaluation.\n\nThe study will evaluate feasibility for a future trial by examining recruitment, retention, return for evaluation, and completion of treatment. It will also explore management strategies for women with non-16\u002F18 hrHPV based on extended genotyping and HPV viral load compared to standard of care approaches using visual inspection with acetic acid (VIA).",[26,27,28,29,30],"Human Papillomavirus (HPV)","HPV Associated Cancers","Cervical Cancer","Human Immunodeficiency Virus (HIV)","Cervical Intraepithelial Neoplasia (CIN)","NOT_YET_RECRUITING","2026-05-04",{"date":34,"type":35},"2026-05-08","ACTUAL",{"date":37,"type":20},"2026-06-01",{"date":39,"type":20},"2027-06-01",{"name":41,"class":42},"University of California, San Diego","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100625933","early-phase-1-effectiveness-of-a-vaginal-gel-on-cin12-regression-and-hpv-clearance-100625933","NCT07429071","Effectiveness of a Vaginal Gel on CIN1\u002F2 Regression and HPV Clearance.","Effectiveness of a Non-Invasive Treatment Using a Vaginal Gel in Promoting HPV Clearance and Regression of Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial.","Inclusion Criteria:\n\n* Positive HPV test\n* Underwent colposcopy with subsequent histopathological findings of CIN1 or CIN2\n* Allocated to a 'watchful waiting' management strategy.\n* Understand Danish, written and orally.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Unexplained bleeding\n* Immunosuppressive\u002Fmodulatory diseases or treatment\n* Cancer or cancer related diseases","30 Years","50 Years",{"count":54,"type":20},70,[56],"EARLY_PHASE1","The goal of this clinical trial is to evaluate whether a Coriolus versicolor-based vaginal gel promotes regression of CIN1\u002FCIN2 and facilitates HPV clearance in women aged 30-50 years diagnosed with CIN1 or CIN2 and HPV. In addition, the study will assess patient satisfaction, treatment compliance and characterize the vaginal microbiome.\n\nThe primary outcomes therefore is:\n\n* the regression of the cervical dysplasia from baseline to the follow-up (6 months), which will be assessed through either liquid-based cytology and\u002For histopathology (biopsy).\n* HPV clearance from baseline to follow-up (6 months)\n\nIn this randomized controlled study, eligible participants will be randomized 1:1 into two groups:\n\n1. Intervention group: Women (n=35) will apply a CV-based vaginal gel (Papilocare®) daily for 21 days for 3 months. Afterward, the gel should be used every other day for an additional 3 months. Every month includes a 7-day break due to menstruation (28 days cycle).\n2. Control group; Women (n=35) will follow the conventional \"wait and see\" approach.",[59,60,30,61,62],"Womens Health","Cervical Dysplasia","Non-invasive Treatment","Human Papilloma Virus (HPV)",[59,60,30,26,64],"Non-Invasive Treatments","2026-03-02",{"date":67,"type":35},"2026-03-04",{"date":69,"type":20},"2026-03",{"date":71,"type":20},"2026-09",{"name":73,"class":42},"University of Aarhus",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":43},"100590463","epidemiological-factors-and-optimization-of-conservative-approaches-to-precancerous-lesions-of-female-reproductive-organs-100590463","NCT06967740","Epidemiological Factors and Optimization of Conservative Approaches to Precancerous Lesions of Female Reproductive Organs","Inclusion Criteria:\n\n* Informed Consent\n* cervical biopsy - HG lesion\n* Age: 18-46 years\n* colposcopicaly visible transformation zone\n* HPV: Unvaccinated\n* cytology all except AIS, adenocarcinoma, squamous cell carcinoma, AGC NEO\n\nExclusion Criteria:\n\n* cytology AIS, AGC NEO, adenocarcinoma, squamous cell carcinoma\n* immunosuppression\n* active autoimmune disease\n* history of cervical cryodestruction\n* HPV vaccinated prior to start of the study","18 Years","46 Years",{"count":83,"type":20},200,"OBSERVATIONAL","The primary aim of this study is to develop a recommended clinical practice guideline for managing women with HPV HR (high-risk human papillomavirus) positivity and cervical lesions. Additionally, in collaboration with the Bioptic Laboratory, the study will analyze the integration of HPV HR testing into screening programs for women aged 35, 45, and 55, with a focus on optimizing management strategies for HPV HR-positive women.\n\nResearch Objectives:\n\n* Evaluate spontaneous regression\u002Fprogression over two years based on HPV HR genotyping (three groups - according to Alinity: high, intermediate, and low risk).\n* Assess spontaneous regression\u002Fprogression over two years based on HPV HR genotyping and viral load in HPV-vaccinated vs. non-vaccinated patients.\n* Evaluate spontaneous regression\u002Fprogression over two years based on methylation results.\n* Assess spontaneous regression\u002Fprogression over two years based on CinTec plus results.",[28,30,87,88],"Risk Factors","Conservative Management",[30,90,91],"Conservative management","Precancerous cervical lesions","RECRUITING","2025-07-29",{"date":95,"type":35},"2025-07-31",{"date":97,"type":35},"2024-11-01",{"date":99,"type":20},"2029-12",{"name":101,"class":102},"Nikola Janovska","OTHER_GOV",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":110,"sex":16,"minAge":80,"maxAge":111,"enrollmentInfo":112,"targetDuration":113,"studyType":84,"phases":4,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":124,"leadSponsor":126,"locationsCount":4},"100567257","correlation-between-selenium-levels-in-human-tissues-and-hpv-related-cervical-lesions-and-outcomes-100567257","NCT06665841","Correlation Between Selenium Levels in Human Tissues and HPV-related Cervical Lesions and Outcomes","SeHPV","Inclusion Criteria:\n\n* Aged 18 to 65 years;\n* No history of sexual activity within the past 3 days;\n* No history of cervical surgery;\n* No history of using contraceptives, hormone therapy, or exposure to metals;\n* No history of cardiovascular, cerebrovascular, liver, kidney, or thyroid diseases;\n* All participants must sign a written informed consent form prior to sampling and agree to cooperate with the study.\n\nExclusion Criteria:\n\n* Previous diagnosis of HPV positivity and those who have received treatment;\n* Pregnant individuals;\n* Individuals who refuse to cooperate.",true,"65 Years",{"count":83,"type":20},"12 Months","This study investigates the relationship between selenium levels in human tissues and the persistence of HPV (human papillomavirus) infection, particularly focusing on cervical-related lesions. The main objectives are to explore the correlation between selenium levels in different body samples (hair, nails, urine, and blood) and to evaluate selenium's potential protective effects against HPV persistence and its progression to cervical lesions.\n\nKey goals of the study include:\n\nDetermining whether non-invasive monitoring (e.g., hair, nails, urine) can accurately reflect blood selenium levels.\n\nUnderstanding how selenium levels fluctuate in women with persistent HPV infection, and whether selenium supplementation can reduce the risk of HPV-related cervical disease progression.\n\nExploring selenium's role in enhancing immune function, especially in older adults, to help clear HPV infection.\n\nBy recruiting volunteers for selenium level testing and tracking HPV-positive women over time, this research aims to provide evidence on the effectiveness of selenium in preventing cervical cancer progression and potentially clearing HPV infections.",[30,28,116],"Persistent HPV Infection",[118,116,119],"Selenium","Cervical Lesions","2024-10-28",{"date":122,"type":35},"2024-10-30",{"date":97,"type":20},{"date":125,"type":20},"2027-12-31",{"name":127,"class":42},"Second Affiliated Hospital of Wenzhou Medical University"]